Viewing Study NCT05644561


Ignite Creation Date: 2025-12-24 @ 12:55 PM
Ignite Modification Date: 2026-01-03 @ 6:47 PM
Study NCT ID: NCT05644561
Status: RECRUITING
Last Update Posted: 2025-12-11
First Post: 2022-12-01
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)
Sponsor: Alexion Pharmaceuticals, Inc.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module